Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.70 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.67 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.67 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059100 | 0.91 | P2RX7 (0.59) | ITGB3ITGA2BITGB1ITGA4ITGB7 | |
| SCHEMBL17822338 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL17822339 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL11232416 | 0.83 | ITGB3 (0.62) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL6480404 | 0.82 | CTSK (0.58) | ITGB3ITGA2B | |
| SCHEMBL21689926 | 0.82 | ITGB1 (0.66) | ITGB3ITGA2BITGB1ITGA4ITGB7 | |
| SCHEMBL7292355 | 0.82 | ITGB3 (0.67) | ITGB3ITGA2BITGB1ITGA4ITGB7 | |
| SCHEMBL11747900 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2BITGAV | |
| SCHEMBL9636970 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2BITGAV | |
| SCHEMBL9157537 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973044-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7968547-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7741328-B2 | Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20070099921-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099921-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB3 13/4885ITGA2B 43/4885ITGB1 29/4885 |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB3 13/4885ITGA2B 43/4885ITGB1 29/4885 |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ITGB3 13/4885ITGA2B 43/4885ITGB1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.